BlackRock Inc. Acquires New Holdings in ADMA Biologics Inc $ADMA

Posted by Geri Gentry on Aug 27th, 2026

BlackRock Inc. bought a new position in ADMA Biologics Inc (NASDAQ:ADMA – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 38,355,684 shares of the biotechnology company’s stock, valued at approximately $321,037,000. BlackRock Inc. owned approximately 0.17% of ADMA Biologics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the company. Summit Securities Group LLC bought a new position in shares of ADMA Biologics during the 4th quarter worth approximately $29,000. Western Wealth Management LLC acquired a new position in shares of ADMA Biologics during the first quarter worth $31,000. iSAM Funds UK Ltd purchased a new stake in shares of ADMA Biologics during the 3rd quarter valued at $34,000. Morse Asset Management Inc purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $44,000. Finally, Nkcfo LLC acquired a new stake in shares of ADMA Biologics in the 4th quarter worth $47,000. 75.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ADMA has been the subject of several recent analyst reports. Wall Street Zen downgraded ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Mizuho decreased their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Canaccord Genuity Group lowered their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Thursday, June 18th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $18.67.

View Our Latest Report on ADMA

ADMA Biologics Trading Down 0.9%

ADMA Biologics stock opened at $9.63 on Thursday. The stock has a 50-day moving average price of $9.03 and a 200 day moving average price of $10.60. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of 13.76 and a beta of 0.74. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $20.46. The company has a quick ratio of 3.81, a current ratio of 6.97 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $124.39 million during the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.14 EPS. Sell-side analysts anticipate that ADMA Biologics Inc will post 0.78 EPS for the current year.

ADMA Biologics Profile

(Free Report)

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.